A

Amgen

Makes biotech medicines for serious illnesses

Equipment Delivery Manager

Full-TimeUpdated on 10/23/2026
€44.6k - €60.3k
Senior
Bachelor's, Master's, PhD, Associate's
Lisbon, Portugal
HybridFlex commuter/hybrid arrangement.
Project & Program ManagementProgram Management

About the job

Requirements
  • A doctorate degree and some years of project controls, source-to-pay, procurement, finance, engineering, capital projects, or related experience; or a master's degree and 5 years of such experience; or a bachelor's degree and 7 years; or an associate's degree and 10 years; or a high school diploma or GED and 12 years.
  • Proficiency in English.
Responsibilities
  • Manage assigned equipment delivery workstreams across projects, equipment packages, suppliers, and global sites based on business needs.
  • Create, maintain, and oversee master equipment registers, package control views, and related tracking tools supporting assigned equipment delivery workstreams.
  • Lead the weekly equipment delivery operating cadence, including package reviews, supplier follow-up summaries, risk, issue and decision logs, escalation summaries, and leadership reporting.
  • Coordinate procurement and buyout readiness activities, including package strategy, supplier assumptions, quotation status, purchase requisition and purchase order readiness, open blockers, and readiness of input packages.
  • Coordinate supplier follow-up and progress tracking in partnership with Engineering, Procurement, Project Management, Supplier Relationship Management, Strategic Sourcing, and supplier relationship channels.
  • Track design submittals and scope interface readiness, including vendor drawings, utility requirements, automation and controls interfaces, layout impacts, design comment resolution, and fabrication readiness.
  • Oversee supplier documentation readiness by tracking expected documentation, due dates, review status, overdue deliverables, rework requirements, and risks impacting Factory Acceptance Testing, Site Acceptance Testing, commissioning, qualification and validation, turnover, and asset readiness.
  • Maintain equipment-specific cost, schedule, and risk visibility, including delivery milestone changes, cost growth indicators, supplier risks, freight and storage risks, change order triggers, and scope interface gaps.
  • Maintain disciplined project trackers, decision logs, package records, and supporting documentation to ensure compliance, traceability, schedule visibility, cost transparency, and audit readiness.
  • Capture package closeout lessons learned, including supplier performance, procurement readiness, documentation quality, cost and schedule performance, design interface issues, and improvement opportunities for future equipment delivery planning.
  • Partner with Engineering, Procurement, Project Controls, Project Management, commissioning, qualification and validation teams, suppliers, analytics, and digital teams to improve reporting, equipment intelligence, and standardized delivery processes.
  • Support continuous improvement initiatives by identifying opportunities to enhance reporting, governance, delivery visibility, and execution across global capital projects.
Desired Qualifications
  • Strong experience supporting capital project delivery, project controls, engineering coordination, equipment delivery, procurement readiness, supplier management, or related project execution activities.
  • Demonstrated ability to lead workstreams, coordinate cross-functional stakeholders, manage package readiness, and drive follow-up through structured governance and escalation.
  • Strong understanding of capital equipment delivery lifecycles, including procurement readiness, supplier progress, design submittals, fabrication, documentation readiness, delivery, installation support, and project closeout.
  • Experience collaborating with Engineering, Procurement, Project Controls, Project Management, commissioning, qualification and validation teams, suppliers, and digital or analytics teams.
  • Experience creating and maintaining equipment registers, reporting dashboards, package trackers, risk registers, decision logs, and project documentation with a high degree of accuracy.
  • Ability to improve cost predictability and delivery visibility by connecting supplier performance, schedule movement, cost indicators, project risks, and equipment status.
  • Experience promoting process compliance, documentation discipline, traceability, and audit readiness across capital project delivery activities.
  • Experience supporting capital projects within pharmaceutical, biotechnology, life sciences, advanced manufacturing, or other regulated industries.
  • Familiarity with Microsoft Excel, Power BI, SharePoint, project management and reporting tools, automation solutions, and artificial intelligence-enabled productivity tools.
  • Experience supporting equipment package tracking, supplier milestone management, documentation readiness, or project reporting activities.
  • Experience working within global organizations, shared service environments, or cross-functional project delivery models.
  • Familiarity with project controls reporting, analytics, reporting standardization, continuous improvement methodologies, and lessons learned programs.
  • Relevant certification in project management, procurement, supply chain, finance, process improvement, or a related discipline is considered an advantage.
  • Demonstrated ability to collaborate effectively across global teams, cultures, and time zones.
  • Ability to simplify complex processes and create practical, scalable ways of working.
  • Strong analytical and problem-solving skills with the ability to identify, escalate, and help resolve project delivery issues.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.